Yosef Yarden

7.7k citations

49 papers · 4.9k indexed · 3 hit papers · h-index 27

Molecular Biology top 2%
Oncology top 2%
Radiology, Nuclear Medicine and Imaging top 2%
Cancer Research top 2%
Immunology top 5%

Co-authors: A. Ullrich Julian Downward Nicholas F. Totty Joseph Schlessinger E. L. V. Mayes Peter A. Stockwell Michael D. Waterfield Sabrina Strano
Topics: HER2/EGFR in Cancer Research (11 papers)Monoclonal and Polyclonal Antibodies Research (9 papers)Lung Cancer Treatments and Mutations (6 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: Israel United States Italy

In The Last Decade

Yosef Yarden

49 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

1984 2.1k citations Julian Downward, Yosef Yarden et al. profile →
ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation

2015 497 citations Mattia Lauriola, Sílvia Carvalho et al. profile →
The circRNA–microRNA code: emerging implications for cancer diagnosis and treatment

2019 332 citations Yosef Yarden et al. profile →

Peers

Countries citing papers authored by Yosef Yarden

Since Specialization

Citations

This map shows the geographic impact of Yosef Yarden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yosef Yarden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yosef Yarden more than expected).

Fields of papers citing papers by Yosef Yarden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yosef Yarden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yosef Yarden. The network helps show where Yosef Yarden may publish in the future.

Co-authorship network of co-authors of Yosef Yarden

This figure shows the co-authorship network connecting the top 25 collaborators of Yosef Yarden. A scholar is included among the top collaborators of Yosef Yarden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yosef Yarden. Yosef Yarden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators 2023 ·Cancers ·Ilaria Marrocco,Yosef Yarden	9
2	Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies 2022 ·Frontiers in Oncology ·(unknown),(unknown),(unknown),Dayana Pérez‐Martínez,(unknown),(unknown),(unknown),(unknown),Moshit Lindzen,Yosef Yarden,(unknown)	1
3	Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma 2021 ·Journal of Biological Chemistry ·Anamika Singh,Ariel Erijman,Ashish Noronha,(unknown),Yoav Peleg,Yosef Yarden,Julia M. Shifman	2
4	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor 2020 ·Cancers ·Donatella Romaniello,Ilaria Marrocco,Nishanth Belugali Nataraj,Irene Ferrer,Diana Drago-García,(unknown),Roni Oren,Moshit Lindzen,Soma Ghosh,(unknown),(unknown),Nadège Gaborit,(unknown),Belinda Sánchez Pérez,Raya Eilam,Eli Pikarsky,Luis Paz‐Ares,Yosef Yarden	40
5	Proteomic patterns associated with response to breast cancer neoadjuvant treatment 2020 ·Molecular Systems Biology ·Anjana Shenoy,Nishanth Belugali Nataraj,Gili Perry,Fabricio Loayza‐Puch,Remco Nagel,(unknown),(unknown),Noa Bossel Ben‐Moshe,(unknown),Iris Barshack,Bella Kaufman,Reuven Agami,Yosef Yarden,Maya Dadiani,Tamar Geiger	38
6	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment 2020 ·Advances in cancer research ·Soma Ghosh,Ilaria Marrocco,Yosef Yarden	39
7	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways 2018 ·Clinical Cancer Research ·Donatella Romaniello,Luigi Mazzeo,Maicol Mancini,Ilaria Marrocco,Ashish Noronha,(unknown),Swati Srivastava,Soma Ghosh,Moshit Lindzen,Tomer‐Meir Salame,Amir Onn,Jair Bar,Yosef Yarden	43
8	Cancer Immunotherapy: The Dawn of Antibody Cocktails 2018 ·Methods in molecular biology ·Ilaria Marrocco,Donatella Romaniello,Yosef Yarden	26
9	Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features 2018 ·Proceedings of the National Academy of Sciences ·Sharathchandra Arandkar,Noa Furth,(unknown),Nishanth Belugali Nataraj,Heiko van der Kuip,Yosef Yarden,Walter E. Aulitzky,Igor Ulitsky,Benjamin Geiger,Moshe Oren	93
10	An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors 2017 ·EMBO Molecular Medicine ·Maicol Mancini,Hilah Gal,Nadège Gaborit,Luigi Mazzeo,Donatella Romaniello,Tomer Meir Salame,Moshit Lindzen,(unknown),Yehoshua Enuka,Dominick G. A. Burton,L. E. Roth,Ashish Noronha,Ilaria Marrocco,(unknown),(unknown),Emilie Bousquet,Julian Downward,Antonio Maraver,Valery Krizhanovsky,Yosef Yarden	42
11	An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors 2015 ·Oncogene ·Sílvia Carvalho,Moshit Lindzen,Mattia Lauriola,(unknown),Sudarson Sekhar Sinha,(unknown),Keren Levanon,Jacob Korach,Iris Barshack,Yaël C. Cohen,Amir Onn,Gordon B. Mills,Yosef Yarden	38
12	Basic cancer research: why it is essentiel for the future of cancer therapy 2014 ·Bulletin du Cancer ·Yosef Yarden,(unknown)	2
13	Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 2013 ·Proceedings of the National Academy of Sciences ·Ruth Maron,Bilha Schechter,Maicol Mancini,(unknown),Yosef Yarden,Michael Sela	37
14	Systems Biology of Growth Factor‐Induced Receptor Endocytosis 2008 ·Traffic ·Yaara Zwang,Yosef Yarden	72
15	Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells 2007 ·Proceedings of the National Academy of Sciences ·Neil L. Spector,Yosef Yarden,Bradley L. Smith,Ljuba Lyass,Patricia B. Trusk,Karen Pry,Jason E. Hill,Wenle Xia,Rony Seger,Sarah Bacus	89
16	Recycling of HER-ErbB Receptors: Rescue From Apoptosis and Targets for Immunotherapy 2002 ·Defense Technical Information Center (DTIC) ·Yosef Yarden	1
17	The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction 1995 ·Cell ·Janna Blechman,Sima Lev,Jacob Barg,Miriam Eisenstein,(unknown),Zvi Vogel,David Givol,Yosef Yarden	142
18	Receptor Tyrosine Kinase Expression in Astrocytic Lesions 1993 ·Neurosurgery ·Donald A. Kristt,(unknown),Yosef Yarden	31
19	c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. 1992 ·Molecular Biology of the Cell ·Yoko Funasaka,Teri G. Boulton,Melanie H. Cobb,Yosef Yarden,Bingbing Fan,SD Lyman,Douglas E. Williams,Dirk Anderson,Rina Zakut,Yuichiro Mishima	145
20	Flg-2, a new member of the family of fibroblast growth factor receptors. 1991 ·PubMed ·A. Avivi,Yitzhak Zimmer,Avner Yayon,Yosef Yarden,David Givol	49

About Yosef Yarden

Yosef Yarden is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 49 papers that have together received 4.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Oncology (1.6k citations), Cancer Research (765 citations) and Molecular Biology (3.2k citations). Yosef Yarden has collaborated with scholars based in Israel, United States and Italy. Frequent co-authors include A. Ullrich, Julian Downward, Nicholas F. Totty, Joseph Schlessinger, E. L. V. Mayes, Peter A. Stockwell, Michael D. Waterfield, Sabrina Strano, Giovanni Blandino and Lorena Verduci. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact